Answers are grounded in this paper and cite their sources.
The oral route may be as effective as the intravenous route for volume expansion for contrast-induced acute kidney injury prevention. Adequately powered trials with hard endpoints should be done given the potential advantages of oral (e.g. reduced patient burden and cost) over intravenous volume expansion.
No takes yet. Share an insight, caveat, or question.
Hiremath et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: